Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
November 3, 2022
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today; joining on this call are Howard Robin, who serves as our President and CEO; Dr. Jonathan Zalevsky, our Chief of Research and Development; Jill Thomsen, our Chief Financial Officer; and Dr. Brian Kotzin, our Chief Medical Officer; during today's call, we anticipate making forward-looking statements about our business, including statements concerning the therapeutic potential of and future development plans for drug candidates in research programs; when clinical studies will be initiated and when clinical data for our drug candidates will become available; the timing and plans for upcoming clinical data presentations, the formation, future development plans or success of our collaboration arrangements; what we expect following our corporate restructuring and reorganization, financial guidance and certain other statements regarding the future of our business. Since forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict, many of which lie outside our control. Our actual results could differ materially from those statements, and significant risks and uncertainties are described in our Form 10-Q filed on August 5, 2022, which can be found at sec.gov; we assume no obligation to update any of these forward-looking statements, whether because of new information, future development or otherwise. A webcast of this call will be accessible on the IR page of our Nektar website at nektar.com. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveAppreciate that, Vivian. And thanks to all of you for being with us today. Through the third quarter, we kept making solid strides in carrying out our new strategic plan, which is aimed at oncology and immunology and centers tightly on three main R&D pillars: NKTR-358, NKTR-255, and our research efforts. With NKTR-358 and NKTR-255, our biologic clinical pipeline is set up to deliver value-boosting clinical trial data starting in 2023 and running through 2025. Just as important, our plan gives us a cash runway extending to the middle of 2025. That's without counting any possible future cash coming in from new partnering work. Every program in our pipeline hands us a unique and very promising chance to bring patients novel potential medicines spanning a range of therapeutic areas. And we're already beginning to see encouraging data across our portfolio. Last quarter, we shared positive results for our clinical-stage immunology program, NKTR-358, now called rezpegaldesleukin, or REZPEG. In atopic dermatitis, REZPEG is being developed alongside our partner, Eli Lilly, and for multiple autoimmune diseases. Beyond atopic dermatitis, we're also going after lupus. We intend to move into at least one more indication, and we're eager to reveal that new indication in the months ahead. Our lupus Phase 2 trial, which enrolled roughly 280 patients, should report topline data in the first half of 2023. And the key Phase 1b data in atopic dermatitis patients presented in Q3 will inform the robust Phase 2b study in that setting, which is also slated to begin in the first part of 2023. That study's design is being finalized right now, and Brian will share more on the REZPEG program shortly. Our second major clinical program is NKTR-255, our novel wholly-owned IL-15 agonist, being developed for both liquid and solid tumors. In large B-cell lymphoma, we remain on track to launch our own sponsored study of NKTR-255 in combination with approved autologous CD19 CAR-T products. These studies are meant to show NKTR-255's potential to boost the efficacy benefit of those therapies. This Phase 2/3 trial will be randomized, double-blind, and placebo-controlled, comparing NKTR-255 against placebo in relapsed or refractory patients receiving CAR-T cells. It will set us up for key comparative data in 2024 for NKTR-255 in second-line and third-line large B-cell lymphoma, the label indication for these approved CAR-T products. In multiple myeloma, we intend to present data from the first several patients enrolled in our study of NKTR-255 combined with DARZALEX FASPRO at the upcoming ASH meeting in New Orleans. The study is still in dose escalation, and we're encouraged by the early data, which keep supporting NKTR-255's biologic mechanism. Specifically, we've seen that NKTR-255 can restore blood NK cell levels following DARZALEX-mediated NK cell clearance. To wrap up, the JAVELIN Bladder Medley Phase 2 comparative trial, which combines treatment with avelumab, started actively enrolling patients during the third quarter. This study is being conducted by our collaborator Merck KGaA, and we remain on schedule to produce PFS data from it before 2024 ends. On the research side, we are developing a novel TNFR2 antibody that, in our view, will be strongly differentiated from everything else in this space and shows considerable potential as a next generation selective Treg agent for autoimmune conditions including multiple sclerosis and inflammatory bowel disease. This marks the first antibody program in our pipeline, and our efforts are centered on moving this important new mechanism forward so that it is ready for IND-enabling studies in 2023. Beyond that, we keep progressing our preclinical oncology efforts: NKTR-288, a novel PEG conjugate of interferon gamma, is intended to alter how interferon gamma binds to its receptor and non-receptor substrates and to optimize how long interferon gamma signaling lasts. At SITC next week, the first set of preclinical data from this program will be presented. We closed the third quarter with roughly $546 million in cash. As I mentioned before, a strategic plan has been put in place that gives us a cash runway extending through the middle of 2025. During this period, we do not expect any need to raise capital. With solid funding and a strong financial position, we will be able to push our key programs toward value generating data and milestones; and at this point, I would like to hand the call over to Brian for an update on REZPEG. Brian?
Brian Kotzin
executiveThank you, Howard. REZPEG is a molecule unlike any other, and the collaboration we have with Eli Lilly on this Treg stimulator — a first-in-class therapy aimed at autoimmune and inflammatory diseases — genuinely has me excited. What we're trying to accomplish with this program is to tackle the Treg deficiencies that sit underneath these conditions, along with the resulting over activity of effector T cells, by activating and expanding Tregs in a selective way. Rather than suppressing the immune system the way immunosuppressive drugs do, REZPEG is built to restore it to a normal balance. Our conviction in this approach kept getting stronger thanks to the data we presented recently in atopic dermatitis. As Howard said, back in September at the EADV Congress, we presented the full dataset from our first initial proof-of-concept study along with moderate-to-severe atopic dermatitis. In that 12-week Phase 1b study run by Lilly, 2 doses of REZPEG were tested against placebo, and patients were then followed for 36 additional weeks once they received their last dose of therapy. Patients given REZPEG experienced a dose dependent reduction in their Eczema Area and Severity Index Scores — also called the EASI score — with roughly a 70% reduction in scores at week-12 at the highest dose tested. We additionally observed a trend toward a dose dependent improvement in the investigator global assessment for atopic dermatitis, along with its responder rates through week-12 of treatment. In line with how REZPEG works, total Tregs and CD25bright Tregs rose versus placebo through week-12. The efficacy seen across the 12 weeks of treatment with REZPEG matches the efficacy seen following 16 weeks of treatment with DUPIXENT, which is the current standard of care for moderate-to-severe disease. But the single most fascinating observation from the study, without question, was this: when we looked at patients 36 weeks after we stopped dosing REZPEG, their skin scores and other measurements of disease remained very low. And that is an effect not observed with DUPIXENT. This has Lilly and us <<inaudible>> highly enthusiastic about the potential for long lasting responses along with infrequent maintenance dosing with REZPEG in the setting of atopic dermatitis. When this program got started at Nektar, our hypothesis was that restoring Treg populations and Treg deficient patients would restore the normal balance in the immune system and potentially provide a disease modifying therapy. Together with Lilly, we coined the term resolution therapeutic to describe the mechanism of REZPEG; we are excited to see the long duration of sustained response observed in the atopic dermatitis study consistent with this hypothesis; in addition, we are encouraged by res REZPEG safety profile, no serious or severe adverse events were reported from patients treated with REZPEG; these collective data support our plan to initiate a Phase 2 study in atopic dermatitis together with Lilly. This will be a relatively large placebo-controlled study; we expect the design of the study to be completed nearly end of the year, and the study to start in the first part of 2023. REZPEG is additionally under assessment in a Phase 2b trial involving individuals whose lupus remains active even while they receive standard background treatments. As a point of reference, this Phase 2 trial is testing 3 dosage strengths of REZPEG against placebo, and roughly 280 subjects across a 24-week course of treatment. Enrollment for the trial is complete, and we remain on schedule to share study results during the first half of 2023. Finally, Lilly is likewise preparing a third Phase 2 trial in an autoimmune indication that has not yet been revealed, which we aim to disclose over the next few months. We have several significant milestones ahead for REZPEG in 2023, and the strong data produced so far strengthen our conviction in this program. We look forward to carrying on our work together with Lilly. With that, I will pass the call to JZ for a discussion of NKTR-255 and our preclinical programs. JZ?
Jonathan Zalevsky
executiveThanks, Brian. So NKTR-255 is one of the therapeutic candidates we're developing, and what it does is engage the whole biology of the IL-15 pathway — it brings functional activation while also providing homeostatic regulation of IL-15 responses within immune cells, and that means natural killer cells, CD8 T-cells, and immune memory subsets specifically. NKTR-255 functions as a full agonist of that pathway, and it's able to signal both through the pathway itself and via transpresentation, the trimeric IL-15 receptor complex. That gives it the ability to be combined with many different mechanisms — anything from targeted agents to cell therapies like CAR-T, and checkpoint inhibitors as well — with the aim of potentially improving how effective those agents are. We're glad to be sharing the initial NKTR-255 data in combination with DARZALEX for multiple myeloma patients at ASH. This trial pairing NKTR-255 with DARZALEX serves as a crucial biological proof of mechanism study for NKTR-255, given the distinctive consequences of how DARZALEX acts. DARZALEX is the antibody targeting CD38 that depletes CD38 positive cells via an ADCC mechanism. DARZALEX works well for treating multiple myeloma because stem cells — the pathogenic tumor cells in multiple myeloma — carry CD38 on their surface and get effectively targeted and depleted by DARZALEX. That said, NK cells likewise carry CD38 on their surface, so those cells also get directly targeted and depleted by DARZALEX. Since NK cells serve as the key immune effector population responsible for driving ADCC, an expanding theory suggests there could be a benefit to restoring NK cell numbers during DARZALEX treatment. Consistent with this idea, we published findings last summer in Blood Advances together with Dr. Nikhil Munshi of Dana-Farber, our collaborator, showing that in many in vitro and in vivo preclinical models, NKTR-255 paired with DARZALEX substantially enhanced the latter's effectiveness against multiple myeloma cells. We are, as Howard mentioned, very encouraged that the initial patients treated with the NKTR-255 plus DARZALEX regimen demonstrated NK cell reconstitution in peripheral blood just days after NKTR-255 dosing began. Enrollment continues in this mechanism proof study, and we've mentioned before that we won't evaluate the mature dose escalation data until we're ready to make a final call on whether to put more money into ADCC combination efforts going forward in this indication. Another priority for us is moving NKTR-255 ahead as an enhancer in the cell therapy space. Autologous CD19 chimeric antigen receptor T cells, known as CAR-T therapy, have seen much broader use in treating B-cell lymphoma since they were first approved a number of years ago. These treatments provide meaningful clinical benefit to patients whose first or second line therapy has failed, yet many of those patients eventually experience relapse after receiving CAR-T. And a significant unmet need exists to provide both a longer duration of response and to generate a greater frequency of complete responses. We've conducted a large number of preclinical studies involving multiple autologous CAR-T therapy. We've shown that adding NKTR-255 can promote cell proliferation and expansion whether antigen is present or not, and it also helps maintain CAR-T cell functionality and prolongs their survival by restricting cell death pathways. Across multiple preclinical models, combining NKTR-255 with CAR-T proves much more effective at tumor clearance than CAR-T by itself. So our clinical hypothesis follows: adding NKTR-255 to a CAR-T regimen might raise CAR-T cell levels, which could lead to better efficacy. As Howard mentioned earlier, we remain on track to launch the Nektar-sponsored trial of NKTR-255 in combination with approved CAR-T therapy. At ASH next month, we'll reveal the trial design for this Phase 2/3 study in patients who have relapsed or refractory diffuse large B-cell lymphoma. This study aims to produce comparative data pitting NKTR-255 plus CAR-T cells against placebo plus CAR-T cells. Our goal is to get the first clinical sites in this study up and running by the close of this year. And as Howard said before, we anticipate initial data during the second half of 2024; we already have two trials running with outside collaborators evaluating NKTR-255 alongside CAR-T therapy. Dr. Two studies are being launched. The first one is under the sponsorship of Crystal MaCkall, who serves as Founding Director of the Stanford Center for Cancer Cell Therapy. In that trial, patients who have relapsed or refractory acute lymphoblastic leukemia will receive a combination of Stanford's proprietary CD19, CD22 bi-specific CAR-T cell therapy along with NKTR-255. The second study is being conducted by Dr. Cameron Turtle's Lab at Fred Hutchinson Cancer Center. At Fred Hutch, NKTR-255 is being combined with Brian's team <<inaudible>>, together with patients who have relapsed or refractory large B-cell lymphoma. Through these 2 studies, the goal is to demonstrate the pharmacodynamics and safety of NKTR-255 cell CAR-T therapy in patients. To put it more precisely, we aim to show that NKTR-255 enhances CAR-T cell expansion, as well as how long those cells persist when treatments are repeated. We're also going to look at how safe NKTR-255 is overall when you start giving it soon after CAR-T cell therapy gets going, and we should have data from the first handful of patients in that trial during 2023. Merck KGaA is another partner we're working with on the NKTR-255 development plan — they've kicked off the JAVELIN Bladder Medley study. In this randomized, open-label Phase 2 trial, avelumab is being paired with 3 antitumor agents and compared: NKTR-255, Fidelvi <<inaudible>>, and an anti-TIGIT candidate that Merck owns. The setting here is maintenance treatment for bladder cancer patients whose disease hasn't gotten worse after a platinum regimen. In this indication, Avelumab's revenue run rate is roughly $500 million on an annualized basis, and depending on how strong the Phase 2 data turn out to be, the study offers NKTR-255 a potential route toward a future registrational trial in this setting. Initial PFS results from that Phase 2 study are anticipated around late 2024. Let's now shift to our preclinical research efforts. We're expanding our research pipeline, with the greatest emphasis currently on biologic programs with potential applications in oncology and immunology. Among the programs under development is NKTR-288, a PEG conjugate of the protein interferon gamma. Interferon gamma is a cytokine responsible for cellular antigen presentation, and it also enhances cytotoxic T cell responses that are specific to tumor antigens. It could prove beneficial in a variety of therapeutic areas, including oncology, infectious disease, and others. With NKTR-288, we've developed a site-specific conjugate of PEG's protein, which alters the way interferon gamma binds to its beta receptors as well as to other binding substrate covered. When combined, this design makes interferon gamma signaling both stronger and longer-lasting from a pharmacodynamic standpoint. In our preclinical work, NKTR-288 raised MHC class 1 and PD-L1 expression on tumors, and it increased antitumor activity in mouse models when administered together with anti-PD-1 or PD-L1; it was also effective by itself as a single agent. At SITC next week, we're looking forward to giving you more data on our NKTR-288 program. Alongside that, work continues at the preclinical stage on our Tumor Necrosis Factor Receptor 2 Program — the TNFR2 program — in combination with biologic design. The goal of this program is to create novel antibodies that function as selective agonists of TNFR2. When it comes to suppressing inflammation and supporting tissue protection and repair, TNFR2 is the essential receptor, signaling only through transmembrane TNF-alpha. One of TNFR2's central functions is fostering Treg stability, homeostasis and function in a range of anatomical tissues. Our knowledge of Treg biology, particularly their differing responses to IL-2 signaling and NF-kappa B signaling, has informed how we're advancing TNFR2 antibody discovery alongside biologic design. There could be value in a TNFR2 agonist across various autoimmune inflammatory conditions — multiple sclerosis, inflammatory bowel disease, arthritis, and antibody mediated autoimmune diseases among them. Should this program reach maturity, we look forward to sharing updates on how it's progressing. At this point, I'll turn things over to Jill, who will walk through our financial guidance. Jill?
Jillian Thomsen
executiveThanks, JZ, and good afternoon to all of you. We closed out the third quarter holding $546 million in cash and investments, with no debt on our books. Our guidance for 2022 finances has not changed, and we anticipate finishing the year with roughly $450 million in cash and investments. Starting in April, we moved quickly to carry out our restructuring and strategic plan, and thanks to that, our financial standing is still solid, with a cash runway reaching into the middle of 2025. That gets us past a number of important value generating milestones for our pipeline. Our team has worked hard to carry out an efficient operational wind down of the BEMPEG program, in line with what we owe to patients and their physicians. Following that plan, every patient across the 6 Nektar run BEMPEG studies has now moved to standard of care or other post-trial treatment options; now, I want to remind everyone about our financial guidance. Our full-year GAAP revenue guidance has not changed and is anticipated to land between $85 million and $95 million, which includes this team to $20 million of product sales, along with $70 million to $75 million in non-cash royalties. We continue to expect recognition of roughly $150 million to $160 million altogether in restructuring and impairment charges tied to ending the BEMPEG program. Our R&D expense is still anticipated to fall between $240 million and $250 million, including $40 million to $45 million in non-cash depreciation and stock compensation expense; and our G&A expense is still projected to land between $90 million and $95 million, including $25 million to $30 million in non-cash depreciation and stock compensation expense. Lastly, our non-cash interest expense is anticipated to be between $25 and $30 million, tied to the earlier monetization of our royalty stream. I want to repeat that we still intend to finish the year with roughly $450 million in cash and investments. And with that, we'll now open the call for questions. Crystal?
Analyst
analystHello, this is Chen <<inaudible>> calling in on behalf of Jay. I appreciate you taking my question, and congratulations on the advancement. Perhaps regarding REZPEG, I'm just curious about your perspective on the unmet need that REZPEG might be able to fill? And do you believe the target population might consist of those who are treated with, well, but respond to DUPIXENT, and possibly if I could ask about 255 in combination with CAR-T? I'm wondering what additional benefits you expect to observe — whether you plan or hope to see greater response rates, let's say, at month 6, where patients might stay disease free for a longer duration. Thank you.
Howard Robin
executiveThank you for asking. When it comes to atopic dermatitis, it's crucial to stress that REZPEG's mechanism differs entirely from every other therapeutic currently under investigation. Given that, it appears quite plausible that individuals who fail to respond to standard of care treatments, such as DUPIXENT or even alternative IL-13 directed therapies, could still respond to a mechanism like REZPEG, which is truly extraordinarily distinct — it works by inducing Tregs to suppress inflammation at the site, without raising immunosuppression; so REZPEG holds this potential regarding the unmet need you mentioned, to reach those who aren't responding, for instance, to other standards — other therapies — standard of care treatments, like, for instance, DUPIXENT, and the IL-13 directed therapies. It's also worth stressing that in our initial data, we observed this truly captivating finding: after we halted therapy, we kept seeing disease suppression. That's genuinely quite extraordinary; and it's this durability of response that also sets us apart from, say, DUPIXENT; so it's conceivable that we could provide this therapy and sustain responses with very infrequent dosing — far less often, for instance, than DUPIXENT, and/or even with no therapy for extended, extended periods, and I believe this is yet another area where we can stand out in this space. So thank you once more for the question.
Vivian Wu
executiveAnd we’ll have JZ, answer the 255 question.
Jonathan Zalevsky
executiveYeah, thanks. So that question concerned what we anticipate from our study. I suppose I'll begin by bringing back to mind a few of those preclinical trials we ran, looking at NKTR-255 alongside various different CAR-T treatments. And what we observe both in vitro and in vivo is whether adding NKTR-255 produces 2 genuinely potent biological impacts, extremely pronounced ones. The first: it brings about a huge enlargement in the maximum count — the peak — of CAR-T cells that multiply within the body once those CAR-T cells have been infused. Keep in mind, these are living drugs; they multiply inside the patient, or inside the test system, whether that's a mouse or whatever. So with 255, you got that big enlargement in cells. The second thing we observe is extended survival of those cells within the animal when treated with 255. You receive both a higher number and greater persistence. And in those preclinical trials, that produces considerable efficacy. Efficacy compared with CAR-T by itself, without 255, is pretty distinct — it's that day-versus-night sort of gap. So then, shifting our focus toward what we expect, we're hoping for comparable sorts of outcomes. We'd like to observe rises in CAR-T cell counts when we give 255 to patients getting one of the approved CAR-T cell regimens, lifting their peak, and we want to boost their persistence and duration. We also want to boost their memory phenotype, sustain and stabilize that phenotype, and keep an activated state in those cells. And then clinically, our hope is this yields two — these two types of measurements; they'd like to see a rise in the complete response rate and how long that complete response rate lasts. As you're aware, one difficulty with these therapies is that the effect fades with time; we want to make that effect endure for as long as we can. And then, in the end, that ought to translate into additional time-to-event endpoints too. Thanks for the question.
Chris Shibutani
analystAfternoon, and thanks. I have a couple of items. First, regarding the pace at which operating expenses are running — clearly a great deal of effort has gone into this year, and the restructuring work has been challenging. When we consider R&D and SG&A outlays, should the figures you reported in the latest quarter serve as our reference? R&D landed under what we and, I believe, consensus had anticipated. For the near to intermediate term looking ahead, is that a fair baseline? Then a second item, maybe directed at Howard. During the quarter, news coverage emerged about a possible merger with PureTech, which could have led to some distinctive potential combinations for your organization. My understanding is those talks were fairly short-lived and then called off — and I think today was, strictly speaking, when that was originally set to conclude. Could you discuss where that originated, and perhaps your strategic thinking? It's evident you have the Lilly partnership, the oncology assets, and so forth. Still, that was an unexpected wrinkle few would have foreseen. If you could offer any remarks on how it arose, and how you and the board are approaching things going forward? That would be great. Thanks.
Jillian Thomsen
executiveHello, Jill here. I'll address the financial one first. To restate: our 2022 guidance remains unchanged. However, thinking ahead to 2023 and our runway through 2025 — at the time we unveiled the restructuring plan last spring, we mentioned that annual burn would trend toward an average of $150 million to $175 million per year across that span. That, I think, is how you should view the cash burn guidance. GAAP may differ somewhat, as you're aware, since it partly hinges on when incurred expenses land. But if GAAP or cash is what you want to concentrate on, I'd say $150 million to $175 million is roughly the correct frame for now. Naturally, we'll provide updated guidance on our February call for 2023.
Howard Robin
executiveHey there, this is Howard. That's a great question. Let me provide a bit of context. I think, look, first off, like I mentioned, back in April, when we brought our strategic plan back out and made revisions to it, I stated we'd be open to hearing from anyone, any business that has any degree of interest in combining operations, and we've definitely kept doing that. And I think just like any business, every so often, we're going to assess offers from other businesses that might help our operations and create that classic one plus one equals three scenario. So PureTech got in touch with us, and we held some conversations with them. Typically, those conversations — we do have conversations — in fact, we have — we're constantly in conversations with businesses. It's something that happens on a routine basis. I can tell you this, though: the sole reason it went public is that, under certain rules — they're a UK company — and under certain UK regulations, it needed to be revealed, even though we were pretty early in the talks. So I wouldn't overanalyze that. What I'd say is we're continually assessing opportunities. And if an opportunity makes sense for our shareholders, we're very keen on chasing it. And beyond that — apart from that, I truly can't say much more about what we're up to on that front. I hope that's useful.
Analyst
analystHello, this is support <<inaudible>> speaking on behalf of Mara. We appreciate you taking our question. I have another inquiry regarding REZPEG. I understand the Phase 2 strategies are being worked out together with Lilly, but I'm simply wondering whether you have any kind of baseline activity you're hoping to observe for the Phase 2 study that began in atopic dermatitis? And, as a follow-up, at what point do you expect to reach the stage of deciding if this would move forward into Phase 3 of a patient directed study? Thank you.
Brian Kotzin
executiveAs we said, we are currently designing the Phase 2b study, and it comes after a proof-of-concept study that was presented. Regarding what we aim to accomplish with the next study, the Phase 2b is essentially meant to completely show the potential efficacy that we'll observe with REZPEG. This will be a study containing fairly standard components. There will likely be an induction phase comparable to other agents, there will be a maintenance phase, and we'll examine various dosing regimens throughout that maintenance phase. And I believe the main things we'll be watching for are: what kind of efficacy, what degree of efficacy do we observe when induction ends? That will be across different patient subgroups. And after that, how does it stack up against other therapies in the space? Then, particularly regarding maintenance, what kinds of infrequent dosing can we — can we attain that sustains the benefit we observe following induction; and naturally, we're hoping for best-in-class type efficacy; so that is what we expect. Thank you.
Analyst
analystThanks.
Roger Song
analystExcellent. I appreciate you answering my question, and congratulations on the advancement. I had a brief inquiry regarding 255 — I follow how the mechanism works, which is that it causes T cells to multiply, so pairing it with CAR-T makes sense. However, I'm just wondering, considering the bi-specifics, especially since they also function somewhat like a passive T cell therapy — do you have any insight into whether 255 could be used alongside those bi-specifics to produce improved efficacy, and why or why not? Thank you.
Jonathan Zalevsky
executiveYes. Hello, Roger, I appreciate the inquiry. This is JZ. To be clear, there's absolutely no scientific or any other obstacle preventing NKTR-255 from being paired with a bi-specific, be it CD3 targeting bi-specifics aimed at T cells, or even an NK cell targeting bi-specific like one with a CD16 arm — actually, both of those represent highly pertinent and sensible possibilities for NKTR-255 too; regarding the underlying mechanisms that might generate potential synergy, correct, between a bi-specific and something like NKTR-255. It's fairly similar to CAR-T. The CAR-T cells carry autoimmune <<inaudible>> receptors, making them a direct target for NKTR-255 here, while with the bi-specific, it would aim at T cells, providing the CD3 positive T cells health along with a CD3 engager, easier targeting, and boosting NK cells with a CD56 engager. Our plan to concentrate on the cell therapy area is clearly because there are more approved agents available in this area. There's obviously a significant unmet need too, even within these approved on labeled indications involving these autologous products. And we believe there's an excellent spot to demonstrate considerable opportunity. Another major factor behind our strong emphasis on the cell therapy area is that a substantial amount of data indicates that IL-15 levels — both those achieved post-conditioning regiment, and those sustained once CAR-T treatment has started — appear to be closely tied to a patient's eventual capacity to generate the strongest, most durable response. So there's also a very compelling scientific rationale for IL-15 and the IL-15 pathway within the healthcare team pathway itself in the health cell therapy context, which is why we opted to concentrate there. But of course, there's a rationale for why we could also incorporate bi-specifics as part of a combination strategy going forward.
Jessica Fye
analystHi there, everyone. Evening. I appreciate you answering my questions. I'd like to know whether you or Lilly plan to reveal the named indication for 358 ahead of the lupus Phase 2 data, or afterward?
Brian Kotzin
executiveThanks for asking. Honestly, at this point we simply don't have that answer. That indication will be announced — or we're hoping to announce it — over the next few months, sometime in the months ahead, though I can't say how that timing lines up with when the lupus study reads out, which is likewise going to happen in early 2023.
Greg Harrison
analystHi everyone, good evening, and I appreciate you taking my question. If REZPEG keeps showing that it's differentiated in atopic derm, how quickly might a pivotal trial be run? And in your best-case scenario, what would that trial look like? I'm just hoping to understand how bigger data catalysts like this one would fit with your cash burn guidance?
Brian Kotzin
executiveI'd say you can look at atypical studies; it really hinges on how large the Phase 2b is, which, as we've mentioned, is being finalized right now in terms of design. That should wrap up around the end of the year. And as we've said, we intend to start the study in the first part of 2023. So for an atypical study, it might run 18 to 24 months, and that's roughly when we'd anticipate getting the data from it.
Andy Hsieh
analystThanks. Appreciate you taking my questions. There are two. First one, perhaps directed at Brian. When you consider the bladder cancer maintenance space and the paths that might win approval in that setting, roughly the middle of next year, I'm wondering whether any sort of strategy exists to potentially become part of that setting, rather than only as a maintenance setting. That's my first question. My second question, perhaps for JZ. You brought up the pivotal CAR-T study, which is extremely interesting. I'd like to know if you could remind us about the explorations that have been done to figure out the optimal sequencing. From earlier questions, you mentioned possibly following the conditioning regimen, or a short while after the infusion, but I'm curious whether that has actually been settled, particularly given Project Optimus, where the FDA is really focusing on picking the correct dose. Thanks for taking my questions.
Jonathan Zalevsky
executiveYes. Thank you, Andy. I believe I can actually address both. The first thing you raised concerned the avelumab setting, correct? At present, avelumab's label covers patients who receive a platinum regimen, meaning a chemo regimen straight away in the first line. After that, patients lacking a complete response become eligible for avelumab maintenance, and as you're aware, it works quite well at keeping patients stable, and it has a good survival figure that they presented, which has been central to securing approval in that setting. Now, it's accurate that there could be some potential PADCEV plus pembro coming soon. Even so, that's still a Phase 3 study that has to finish and reach its conclusion. It could happen. We continually examine whether that alters the first-line landscape, so for instance, does it begin to erode or push aside that first-line chemo, which is where avelumab gets used. That's a piece we're watching and monitoring. And you can picture that our collaborator, Merck KGaA, is watching that even more closely, so we're very attuned to it too. Then, over the longer term, based on what results emerge in this maintenance setting and what we discover in the bladder. Yes, I think an opportunity exists for further expansion, with additional lines to be assessed too, possibly even in that Pembro PADCEV regimen, should that regimen gain approval. So that's sort of a crystal ball type of question. The next thing you raised concerned the CAR-T setting. And I think you asked a truly excellent question. You've got it — I brought up Project Optimus, the choice of dose and the choice of regimen. That was something we devoted considerable attention to in our preclinical studies. We ran several studies alongside our collaborator Cameron Turtle from Fred Hutch, and in those we used the identical autologous CD19 CAR-T, evaluating various dose ranges plus dose levels of NKTR-255, and also when NKTR-255 was given in relation to the CAR-T cell infusion. That's an area where we invested a great deal of effort and a great deal of resources, when we revealed the outline of that Phase 2/3 study we're going to sponsor. And like I said, we'll be revealing it at ASH during an event we put on. There you'll get far more detail on how we're tackling your question head-on, with extremely careful attention paid to both the dose level and the dose regimen, which matters so much when used in cellular therapy. And the reason it carries special weight in cell therapy settings — well, we must always keep in mind that these drugs are essentially living medicines, correct? The cells multiply, their CD19 is positive, plenty of B-cells express CD19, so there's abundant antigen available for the cell to multiply against, proliferating through an antigen-driven response. Therefore, applying NKTR-255 to extend and maintain that proliferation, along with the overall cell population and its fitness, is something for which both the regimen and the doses matter greatly. So we're eager to share our strategy on that with all of you essentially next month.
Howard Robin
executiveWe appreciate all of you being here today; and as we've mentioned — I believe we've described how we keep moving forward, effectively carrying out our plan. Also, our pipeline along with partner programs keep progressing and could potentially meet the requirements of large patient groups and offer the chance to generate considerable worth for those who hold our stock. Thus, I want to express gratitude to every one of our staff members for what they do and their dedication; and I also wish to thank our investors for their ongoing backing <<inaudible>> some news on how we're doing. So keep watching. Many thanks.
Operator
operatorThanks so much. That brings today’s conference call to a close. We appreciate everyone joining us. At this point, please feel free to disconnect. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.